Hepatitis B virus mutants: Clinical significance for diagnosis and therapy;Hepatitis-B-Virusmutanten - Klinische Bedeutung

Zeitschrift fur Gastroenterologie

Volumn 35, Issue 5, 1997, Pages 347-355

  Blum, H E ^a,b   Moradpour, D ^a   Von Weizsacker F ^a   Wieland, S ^a   Peters, Th ^a   Rasenack, J W S ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

hepatitis B virus; mutants; quasi species; variants

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; RNA DIRECTED DNA POLYMERASE;

CHRONIC HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; PERSISTENT VIRUS INFECTION; REVIEW; SEROCONVERSION; VIRUS MUTANT;

ANTIBODY FORMATION; GENES, VIRAL; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS, CHRONIC; HUMANS; MUTATION; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0030959360     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Blum HE. Hepatitisviren und Leberkarzinom. Deutsches Ärzteblatt 1993; 90: C1665-C9
2. Lau JYN, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335-40
3. Wright TL, Lau JYN. Clinical aspects of hepatitis B virus infection. Lancet 1993; 342: 1340-4
4. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-15
5. Carman W, Thomas H, Domingo E. Viral genetic variation: Hepatitis B virus as a clinical example. Lancet 1993; 341: 349-53
6. Domingo E, Sabo D, Taniguchi T, Weissmann C. Nucleotide sequence heterogeneity of an RNA phage population. Cell 1978; 13: 734-44
7. Chen HS, Kew MC, Hornbuckle WE et al. The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host. J Virol 1992; 66: 5682-4
8. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483-9
9. Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170: 595-7
10. Nowak MA, Bonhoeffer S, Hill AM et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-402
11. Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-9
12. Harrison TJ, Hopes EA, Oon CJ, Zanetti AR, Zuckerman AJ. Independent emergence of a vaccine-induced escape mutant of hepatitis B virus. J Hepatol 1991; 13 (suppl. 4): S105-S7
13. Waters JA, Kennedy M, Voet P et al. Loss of the common »a« determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992; 90: 2543-7
14. Fujii H, Moriyama K, Sakamoto N et al. Gly145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus. Biochem Biophys Res Commun 1992; 184: 1152-7
15. Okamoto H, Yano K, Nozaki Y et al. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatric Res 1992; 32: 264-8
16. Ni F, Fang D, Gan R et al. A new immune escape mutant of hepatitis B virus with an Asp to Ala substitution in aa144 of the envelope major protein. Res Virol 1995; 146: 397-407
17. McMahon G, Ehrlich PH, Moustafa ZA et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibodytreated liver transplant patients. Hepatology 1992; 15: 757-66
18. Carman WF, Trautwein C, van Deursen FJ et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489-93
19. Yamamoto K, Horikita M, Tsuda F et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994; 68; 2671-6
20. Fernholz D, Galle PR, Stemler M et al. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology 1993; 194: 137-48
21. Gerken G, Kremsdorf D, Capel F et al. Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV infection. Virology 1991; 183: 555-65
22. Xu Z, Yen TSB. Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J Virol 1996; 70: 133-40
23. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 94: 230-9
24. Kato J, Hasegawa K, Torri N, Yamauchi K, Hayashi N. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. Hepatology 1996; 389-95
25. Akahane Y, Yamanaka T, Suzuki H et al. Chronic active hepatitis with hepatitis B virus DNA and an tibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990; 99: 1113-9
26. Brunetto MR, Stemler M, Bonino F et al. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol 1990; 10: 258-61
27. Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91
28. Kosaka Y, Takase K, Kojima M et al. Fulminant hepatitis B: Induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991; 100: 1087-94
29. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324: 1705-9
30. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324: 1699-704
31. Aye TT, Uchida T, Backer SO et al. Variations of hepatitis B virus precore/core gene sequence in acute and fulminant hepatitis B. Dig Dis Sci 1994; 39: 1281-7
32. Sato S, Suzuki K, Akahane Y et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122: 241-8
33. Lee YI, Hur GM, Suh D-J, Kim SH. Novel pre-C/C gene mutants of hepatitis B virus in chronic active hepatitis: Naturally occurring escape mutants. J Gen Virol 1996; 77: 1129-38
34. Naoumov NV, Schneider R, Grotzinger T et al. Pre-core mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102: 538-43
35. Lai ME, Solinas A, Mazzoleni AP et al. The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. J Hepatol 1994; 20: 773-81
36. Okamoto H, Yotsumoto S, Akahane Y et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64: 1298-303
37. Omi S, Okamoto H, Tsuda F, Mayumi M. Defects in the precore region of hepatitis B virus DNA in a plasma pool from carriers seropositive for antibody against e antigen and with infectivity in chimpanzees. J Gastroenterol Hepatol 1990; 5: 646-52
38. Tur Kaspa R, Klein A, Aharonson S. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology 1992; 16: 1338-42
39. Akarca US, Greene S, Lok AS. Detection of precore hepatitis B virus mutants in asymptomatic HBsAg-positive family members. Hepatology 1994; 19: 1366-70
40. Laskus T, Persing DH, Nowicki MJ, Mosley JW, Rakela J. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. Gastroenterology 1993; 105: 1173-8
41. Li I-S, Tong S-P, Wen Y-M et al. Hepatitis B virus genotype a rarely circulates as an HBe-minus mutant: Possible contribution of a single nucleotide in the precore region. J Virol 1993; 67: 5402-10
42. Rodriguez-Frias F, Buti M, Jardi R et al. Hepatitis B virus infection: Precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22: 1641-7
43. Lindh M, Horal P, Dhillon AP, Furuty Y, Norkrans G. Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage. Hepatology 1996; 24: 494-501
44. Ehata T, Omata M, Chuang WL et al. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest 1993; 91: 1206-13
45. Ehata T, Omata M, Yokosuka O, Hosoda K, Ohto M. Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection. J Clin Invest 1992; 89: 332-8
46. Wakita T, Kakumu S, Shibata M et al. Detection of pre-C and core region mutants of hepatitis B virus in chronic hepatitis B virus carriers. J Clin Invest 1991; 88: 1793-801
47. Akarca US, Lok AS. Naturally occurring hepatitis B virus core gene mutations. Hepatology 1995; 22: 50-60
48. Günther S, Baginski S, Kissel H et al. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology 1996; 24: 751-8
49. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
50. Karayiannis P, Alexopoulou A, Hadziyannis S et al. Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: Importance of host factors. Hepatology 1995; 22: 1628-34
51. Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 1993; 361: 742-5
52. Wang XW, Gibson MK, Vermeulen W et al. Abrogation of p53-induced apoptosis by the hepatitis B virus × gene. Cancer Res 1995; 55: 6012-6
53. Lee T-H, Elledge SJ, Butel JS. Hepatitis B virus × protein interacts with a probable cellular DNA repair protein. J Virol 1995; 69: 1107-14
54. Lee H, Lee Y-H, Huh Y-S, Moon H, Yun Y. X-gene product antagonizes the p53-mediated inhibition of hepatitis B virus replication through regulation of the pregenomic/core promoter. J Biol Chem 1995; 270: 31405-12
55. Benn J, Schneider RJ. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci USA 1995; 92: 11215-9
56. Blum HE, Galun E, Liang TJ, von Weizsäcker F, Wands JR. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 1991; 65: 1836-42
57. Tipples GA, Ma MM, Fischer KP et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance of lamivudine in vivo. Hepatology 1996; 24: 714-7
58. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-3
59. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2
60. Bain VG, Knetemann NM, Ma MM et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 1456-62
61. Aye TT, Bartholomeusz A, Shaw T et al. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation. Hepatology 1996; 24: 285A
62. Laskus T, Rakela J, Tong MJ et al. Naturally occurring hepatitis B virus mutants with deletions in the core promoter region. J Hepatol 1994; 20: 837-41
63. Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carrier with antibody to e antigen. J Virol 1994; 68: 8102-10
64. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promoter mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98: 2268-76
65. Laskus T, Rakela J, Steers JL, Wiesner RH, Persing DH. Precore and contiguous regions of hepatitis B virus in liver transplantation or end-stage hepatitis B. Gastroenterology 1994; 107: 1774-80
66. Pult I, Chouard T, Wieland S et al. A hepatitis B virus mutant with a new hepatocyte factor binding site emerging in transplant transmitted fulminant hepatitis B. Hepatology 1997; 25: in press
67. McMillian JS, Bowden DS, Angus PW, McCaughan GW, Locarnini SA. Mutations in the hepatitis B virus precore/core gene and core promotor in patients with severe recurrent disease following liver transplantation. Hepatology 1996; 24: 1371-8
68. Blum HE. Variants of hepatitis B, C an D viruses: Molecular biology and clinical significance. Digestion 1995; 56: 85-95
69. Sterneck M, Günther S, Santantonio T et al. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology 1996; 24: 300-6
70. Bertolletti A, Sette A, Chisari FV et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369: 407-10
71. Barbera C, Calvo P, Coscia A et al. Precore mutant hepatitis B virus and outcome of chronic infection in hepatitis B e antigen-positive children. Pediatric Res 1994; 36: 347-50
72. Brunetto MR, Giarin M, Saracco G et al. Hepatitis B virus unable to secrete e antigen and response to Interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845-50
73. Fattovich G, Farci P, Rugge M et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15: 584-9
74. Xu J, Brown D, Harrison T, Lin Y, Dusheiko G. Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to inter-feron-alpha. Hepatology 1992; 15: 1002-6
75. Fattovich G, McIntyre G, Thursz M et al. Hepatitis B virus precore/core variation and Interferon therapy. Hepatology 1995; 22: 1355-62
76. Naoumov NV, Thomas MG, Mason AL et al. Genomic variations in the hepatitis B core gene: A possible factor influencing response to Interferon alfa treatment. Gastroenterology 1995; 108: 505-14
77. Lok AS. Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma? Hepatology 1995; 22: 1336-8
78. Günther S, Meisel H, Reip A et al. Frequent and rapid emergence of mutated pre-c sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology 1992; 187: 271-9
79. Ayola B, Ghany MG, Villamil FG et al. HBIG induced HBV S gene mutations in liver transplant (LT) recipients can revert after withdrawal of HBIG. Hepatology 1996; 24: 182A